CEM to reconvene its popular 'Methods in Bioengineering' conference on July 14-15

The Center for Engineering in Medicine (CEM) -- a bioengineering research institute at the Massachusetts General Hospital (MGH), a Harvard Teaching Hospital -- has announced it will reconvene its popular "Methods in Bioengineering" conference in conjunction with event organizer Horizon House Ltd. The event, BioMethods Boston, will take place at Harvard Medical School on July 14-15, and expects to draw over 400 senior researchers from the Boston biotech community.

BioMethods Boston has confirmed program participation from Harvard, MIT, Boston University, Northeastern, WPI, and Tufts, plus top-tier pharma companies like Millipore, Life Technologies, and Genzyme, as well as major health centers like Mass General Hospital and Children's Hospital Boston.

BioMethods Boston’s agenda will include sessions on stem cell therapies, functional imaging, BioMEMS, nanotechnologies, and gene delivery. A call for posters has just been announced, and an automated interface for submissions, as well as the nearly-complete agenda, can be accessed at the event website (www.biomethodsboston.com). "This event is designed to give biomedical investigators from all fields a clear perspective on the most advanced technologies, techniques, and methodologies, and an opportunity for attendees to network with top researchers in the field," says Dr. Martin Yarmush, Director of the CEM.

Yarmush is joined on the program committee by Dr. Robert Langer of MIT, named by Forbes' magazine as one of the 25 most important people in biotechnology, as well as Dr. James Burns, SVP, Drug & Biomaterial R&D at Genzyme Corp., Dr. Donald Ingber, Director, Wyss Institute for Biologically Inspired Engineering at Harvard, Dr. Joachim Kohn, Director, New Jersey Center for Biomaterials at Rutgers, Dr. Mehmet Toner, Director, BioMEMS Resource Center at MGH, Dr. Kyongbum Lee, Department Chair, Chemical & Biological Engineering at Tufts, and Dr. Mahendra Rao, VP, Stem Cells & Regenerative Medicine at Invitrogen/Life Technologies -- among many others.

SOURCE Horizon House Ltd.